FDA Panel Endorses Riociguat For CTEPH Amid Worries It Will Displace Surgery
Executive Summary
Committee unanimously recommends Bayer’s Adempas for two indications, but members say measures are needed to ensure that patients with chronic thromboembolic pulmonary hypertension are not automatically steered to the novel vasodilator when they could benefit from potentially curative surgery.